路透 - 视频

版本: US | UK | IN | CN | JP

video

Breakingviews TV: Drug dreams

2018年 11月 29日 星期四 - 02:56

Moderna’s hoped-for $8 bln IPO valuation is a rich antidote to the funk hitting tech stocks. Rob Cyran explains that although the biotech firm’s technology is promising, it has no drugs near commercial readiness. That’s all the more reason to grab the money while it can.

▲ 隐藏详情

显示详情

Moderna’s hoped-for $8 bln IPO valuation is a rich antidote to the funk hitting tech stocks. Rob Cyran explains that although the biotech firm’s technology is promising, it has no drugs near commercial readiness. That’s all the more reason to grab the money while it can.

分享到  - 微信
路透中文网

Breakingviews TV: Drug dreams

2018年 11月 29日 星期四 - 02:56